MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells
Authors
Keywords
-
Journal
Oncogenesis
Volume 7, Issue 9, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-06
DOI
10.1038/s41389-018-0078-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FBW7 -Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors
- (2017) Jingshan Tong et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
- (2017) A N Hata et al. ONCOGENE
- Combined MEK and Pi3’-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo
- (2017) Oussama ElMokh et al. Oncotarget
- FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
- (2016) J Tong et al. ONCOGENE
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma
- (2015) U Heinicke et al. ONCOGENE
- Subcellular localization of PUMA regulates its pro-apoptotic activity in Burkitt’s lymphoma B cells
- (2015) Gorbatchev Ambroise et al. Oncotarget
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
- (2015) Sarah J. Welsh et al. Therapeutic Advances in Medical Oncology
- Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
- (2014) D. Chen et al. CLINICAL CANCER RESEARCH
- The Biology and Clinical Development of MEK Inhibitors for Cancer
- (2014) Jason J. Luke et al. DRUGS
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- (2014) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- Mutations of theBRAFgene in human cancer, by Davieset al. (Nature2002; 417: 949-54)
- (2013) G. W. M. Millington CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
- (2013) F. Catalanotti et al. CLINICAL CANCER RESEARCH
- Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells
- (2013) X. Zheng et al. MOLECULAR CANCER THERAPEUTICS
- BIM, PUMA, and the Achilles' Heel of Oncogene Addiction
- (2013) A. Roulston et al. Science Signaling
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice
- (2011) Wei Qiu et al. HEPATOLOGY
- PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice
- (2011) Wei Qiu et al. JOURNAL OF CLINICAL INVESTIGATION
- PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01
- (2010) C. Dudgeon et al. MOLECULAR CANCER THERAPEUTICS
- PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells
- (2009) Q Sun et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search